MedTrace Logo

Effectiveness and Safety of Platelet-rich Plasma and Topical 5% Minoxidil Combination in Male Androgenetic Alopecia

NCT06043349 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2023-09-21

No results posted yet for this study

Summary

The goal of this clinical trial is to learn about the effectiveness and safety of platelet-rich plasma (PRP) and topical 5% minoxidil combination therapy compared with topical 5% minoxidil monotherapy in male androgenetic alopecia.

The main questions it aims to answer are:

* Is there a difference in average change of hair density between groups that were given a combination of PRP injection and topical minoxidil compared to topical minoxidil as monotherapy?
* Is there a difference in average change of hair thickness between groups that were given a combination of PRP and topical minoxidil compared to topical minoxidil as monotherapy?
* Are there any differences in side effects between groups that were given combination of PRP and topical minoxidil compared to topical minoxidil as monotherapy?

Conditions

Interventions

COMBINATION_PRODUCT

Platelet-Rich Plasma and Topical 5% Minoxidil

The intervention group will receive three PRP injections during three months in addition to the topical 5% minoxidil.

DRUG

Topical 5% Minoxidil

The intervention group will receive topical 5% minoxidil as standard therapy for male androgenetic alopecia.

Sponsors & Collaborators

  • Indonesia University

    lead OTHER

Principal Investigators

  • Adhika A Lestari, MD · Faculty of Medicine, University of Indonesia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2023-09-01
Completion
2023-09-30

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06043349 on ClinicalTrials.gov